Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ArtiQ logo — Providing AI software to optimize clinical trials and enhan...

ArtiQ

Providing AI software to optimize clinical trials and enhance diagnostic processes to improve patients' lives worldwide

Founded 2019 Belgium Belgium 20 employees Acquired Total: $1.15M AI, Biotechnology +2

General Information

Company Name ArtiQ
Founded Year 2019
Location Belgium Belgium
Employees 20
Industries AI, Biotechnology, Health Care +1
Funding Stage Acquired
Business Model SaaS, B2B, B2B2B
Revenue Model Subscription, Tiered Pricing, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with ArtiQ. To contact ArtiQ, visit artiq.eu.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About ArtiQ

ArtiQ, a spin-off from the Belgian university KU Leuven, is rapidly emerging as an innovator in the diagnosis and management of respiratory conditions. This 2019-established company operates at the intersection of AI, Biotechnology, Health Care, and Information Technology, providing AI-driven software to optimize clinical trials and enhance diagnostic processes.

In April 2024, ArtiQ entered a pivotal phase of its journey through an acquisition investment led by Clario, a prominent healthcare research and technology leader. This strategic partnership allows ArtiQ to extend its global reach across various clinical trials, broadening its impact beyond respiratory care and contributing to healthcare improvements worldwide.

Headquartered in Belgium, ArtiQ's collaboration with Clario marks a significant milestone, enhancing its capacity to offer innovative solutions to pharmaceutical companies, optimizing respiratory clinical trials, and empowering traditional diagnostic devices with cutting-edge AI-first software.

Taxonomy: AI Software, Clinical Trials Optimization, Respiratory Diagnostics, Pulmonary Function Tests, Respiratory Medicine, AI-based Medical Solutions, Digital Health, Diagnostic Processes, Decision Support Systems, Healthcare Partnerships, Pharmaceutical Clinical Trials, Respiratory Care Innovation

Services & Products

AI-supported interpretation of pulmonary function tests
Automated spirometry quality assessment
AI-based risk monitoring
Clinical trial data optimization

Target Customers

Medical doctors specializing in respiratory diseases Pharmaceutical companies Clinical researchers Healthcare providers and institutions

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition Undisclosed 1
Clario
01 Apr 2024
Support Program €1.50K 1
EIT Health
01 Oct 2020
Grant €10.00K 1
EIT Health
01 Jun 2020
Support Program €10.00K 1
EIT Health
01 Jan 2020
Support Program $1.13M 3
KBC, Gemma Frisius Fund - GFF +1
01 Jul 2019
Spinout Undisclosed 1
Start it @KBC
01 Mar 2019

Latest News

View All
Clario acquires WCG's neuroscience-focused clinical outcome assessment business — Fiercebiotech.com
Clario acquires WCG's neuroscience-focused clinical outcome assessment business
Fiercebiotech.com Mar 12, 2025
Clario buys AI firm ArtiQ, taps CEO to head AI strategy — Fiercebiotech.com
Clario buys AI firm ArtiQ, taps CEO to head AI strategy
Fiercebiotech.com Apr 03, 2024
Clario announces acquisition of AI-powered software company ArtiQ — Prnewswire.com
Clario announces acquisition of AI-powered software company ArtiQ
Prnewswire.com Apr 02, 2024

ArtiQ Alternatives & Competitors

View All Alternatives
ArtiQ vs
Hyfe
Hyfe United States

AI-powered cough-tracking & insights. Precision medicine for respiratory health

Seed
44 employees
AI, Health Care
ArtiQ vs
Onc.AI
Onc.AI United States

Non-invasive radiomic-based biomarkers for clinical decision support

Series A
27 employees
Biotechnology, Health Care
ArtiQ vs
Deep Breath 🫁
Deep Breath 🫁 The Netherlands

Better ICU care is here. Just ask the data.

Seed
8 employees
AI, Health Care
View all alternatives

FAQ About ArtiQ

Providing AI software to optimize clinical trials and enhance diagnostic processes to improve patients' lives worldwide
ArtiQ was founded in 2019.
ArtiQ is headquartered in Belgium.
ArtiQ operates in AI, Biotechnology, Health Care and Information Technology. Its work centres on AI Software, Clinical Trials Optimization, Respiratory Diagnostics and Pulmonary Function Tests. Its customers include Medical doctors specializing in respiratory diseases, Pharmaceutical companies and Clinical researchers.
ArtiQ has a SaaS, B2B and B2B2B business model. Its revenue comes from Subscription, Tiered Pricing and Usage Based.
ArtiQ has approximately 20 employees.
ArtiQ has completed 6 funding rounds, raising a total of $1.15M. The latest funding stage is Acquired.
ArtiQ offers: AI-supported interpretation of pulmonary function tests, Automated spirometry quality assessment, AI-based risk monitoring, Clinical trial data optimization.
Top alternatives and competitors to ArtiQ include Hyfe, Onc.AI, Deep Breath 🫁, Massive Bio, Xolomon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ArtiQ and Hyfe are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ArtiQ, https://bouncewatch.com/company/artiq, updated 6 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes